Tag Archives: Pediatric

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Care Options for Pediatric Patients Before, During and After Hurricane Florence

With Hurricane Florence setting its sights on the Carolinas, the storm is likely to affect western North Carolina later this week, through the weekend and into the beginning of next week. Since Tuesday, more than 1.5 million people have been ordered to evacuate 300 miles along the mid- to south- Atlantic coasts; evacuees are seeking… Read More »